Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4c02142090911c1578ebb9332a4f2df4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y115-01001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
filingDate |
2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e42ea3d2f77cfc7c43a17e19b51cd4a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_415f47e130b58b7284138ab930ba8f65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34297c95a03f2188413d8380b3ad0956 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_874de3247868497723c32f1a7156f415 |
publicationDate |
2022-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20220027059-A |
titleOfInvention |
Treatment of SOD1-related diseases |
abstract |
The present invention relates to antisense oligonucleotides that are complementary to SOD1, resulting in reduced expression of SOD1. Reduced expression of SOD1 is beneficial for medical disorders such as amyotrophic lateral sclerosis. |
priorityDate |
2019-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |